NCI CAM News Now Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 6
Volume 15
Issue 6

The National Cancer Institute (NCI) has begun publishing a free biannual newsletter that focuses on the agency's activities in the area of complementary and alternative medicine (CAM). NCI CAM News, produced by NCI's Office of Cancer Complementary and Alternative Medicine, is available online.

BETHESDA, Maryland—The National Cancer Institute (NCI) has begun publishing a free biannual newsletter that focuses on the agency's activities in the area of complementary and alternative medicine (CAM). NCI CAM News, produced by NCI's Office of Cancer Complementary and Alternative Medicine, is available online at http://www.cancer.gov/cam/newsletter/home.html. For a subscription, go to https://list.nih.gov/cgi-bin/wa?SUBED1=nci_cam_news&A=1.

Articles in this issue
Triple-Negative Cancers More Common in Young Black Pts
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'
Study to Examine Outcomes Disparities in Pediatric ALL
Thalidomide Has 'Changed the Paradigm' in Myeloma Rx
CA4P Gets Orphan Drug Status
Testicular Ca Survivors at Increased Risk for CV Events
A Novel Brings a Cancer Research Laboratory to Life
NCCN Reveals New Venous Thromboembolism Guideline
Lapatinib New Option for Metastatic HER2+ Breast Ca
FDA Approves Dacogen for Treating All MDS Subtypes
Noninvasive Ablation Relieves Chronic Chest Wall Pain
GVAX Receives Fast-Track Status
Medicare CAP Vendor Selected
Selective IGF-1R Inhibitor Blocks Colon Cancer Growth
US Cancer Mortality Drops
Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content
Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.

Capivasertib Combo Significantly Improves rPFS in PTEN-Deficient HSPC

Russ Conroy
November 25th 2024
Article

Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Site Logo

SPM AE Incidence After CAR T-Cell Therapy in Lymphoma and Myeloma

American Society for Transplantation and Cellular Therapy
November 25th 2024
Article

Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab vs lenalidomide alone as post-transplant maintenance therapy for patients with newly diagnosed multiple myeloma.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma

Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma

Tim Cortese
November 25th 2024
Article

A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.

The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.

VIOLETTE Trial Shows Precise Planning in Prostate Cancer Microwave Ablation

Tim Cortese
November 22nd 2024
Article

The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.